Shaw K, A Zello G, Bandy B, Ko J, Bertrand L, Chilibeck P
Nutrients. 2021; 13(6).
PMID: 34208239
PMC: 8230900.
DOI: 10.3390/nu13062016.
Clarke H, Hickner R, Ormsbee M
Nutrients. 2021; 13(3).
PMID: 33807747
PMC: 7999364.
DOI: 10.3390/nu13030857.
Clarke H, Kim D, Meza C, Ormsbee M, Hickner R
Nutrients. 2020; 12(9).
PMID: 32947909
PMC: 7551337.
DOI: 10.3390/nu12092834.
Wadman R, van der Pol W, Bosboom W, Asselman F, van den Berg L, Iannaccone S
Cochrane Database Syst Rev. 2020; 1:CD006282.
PMID: 32006461
PMC: 6995983.
DOI: 10.1002/14651858.CD006282.pub5.
Juhasz I, Kopkane J, Hajdu P, Szalay G, Kopper B, Tihanyi J
J Sports Sci Med. 2018; 17(2):279-288.
PMID: 29769829
PMC: 5950745.
Creatine Prevents the Structural and Functional Damage to Mitochondria in Myogenic, Oxidatively Stressed C2C12 Cells and Restores Their Differentiation Capacity.
Barbieri E, Guescini M, Calcabrini C, Vallorani L, Diaz A, Fimognari C
Oxid Med Cell Longev. 2016; 2016:5152029.
PMID: 27610211
PMC: 5005540.
DOI: 10.1155/2016/5152029.
Metabogenic and Nutriceutical Approaches to Address Energy Dysregulation and Skeletal Muscle Wasting in Duchenne Muscular Dystrophy.
Rybalka E, Timpani C, Stathis C, Hayes A, Cooke M
Nutrients. 2015; 7(12):9734-67.
PMID: 26703720
PMC: 4690050.
DOI: 10.3390/nu7125498.
Creatine, L-carnitine, and ω3 polyunsaturated fatty acid supplementation from healthy to diseased skeletal muscle.
DAntona G, Nabavi S, Micheletti P, Di Lorenzo A, Aquilani R, Nisoli E
Biomed Res Int. 2014; 2014:613890.
PMID: 25243159
PMC: 4163371.
DOI: 10.1155/2014/613890.
Creatine supplementation induces alteration in cross-sectional area in skeletal muscle fibers of wistar rats under swimming training.
Moura I, Santos F, Moura J, Curi R, Fernandes L
J Sports Sci Med. 2014; 1(3):87-95.
PMID: 24701129
PMC: 3967434.
Creatine for treating muscle disorders.
Kley R, Tarnopolsky M, Vorgerd M
Cochrane Database Syst Rev. 2013; (6):CD004760.
PMID: 23740606
PMC: 6492334.
DOI: 10.1002/14651858.CD004760.pub4.
Treatment for mitochondrial disorders.
Pfeffer G, Majamaa K, Turnbull D, Thorburn D, Chinnery P
Cochrane Database Syst Rev. 2012; (4):CD004426.
PMID: 22513923
PMC: 7201312.
DOI: 10.1002/14651858.CD004426.pub3.
Mitochondrial therapy for Parkinson's disease: neuroprotective pharmaconutrition may be disease-modifying.
Kones R
Clin Pharmacol. 2012; 2:185-98.
PMID: 22291504
PMC: 3262379.
DOI: 10.2147/CPAA.S12082.
Creatine monohydrate in ALS: effects on strength, fatigue, respiratory status and ALSFRS.
Rosenfeld J, King R, Jackson C, Bedlack R, Barohn R, Dick A
Amyotroph Lateral Scler. 2008; 9(5):266-72.
PMID: 18608103
PMC: 2631354.
DOI: 10.1080/17482960802028890.
Therapeutics in duchenne muscular dystrophy.
Strober J
NeuroRx. 2006; 3(2):225-34.
PMID: 16554260
PMC: 3593432.
DOI: 10.1016/j.nurx.2006.01.005.
The role of creatine in the management of amyotrophic lateral sclerosis and other neurodegenerative disorders.
Ellis A, Rosenfeld J
CNS Drugs. 2004; 18(14):967-80.
PMID: 15584767
DOI: 10.2165/00023210-200418140-00002.
Spinal muscular atrophy.
Iannaccone S, Smith S, Simard L
Curr Neurol Neurosci Rep. 2003; 4(1):74-80.
PMID: 14683633
DOI: 10.1007/s11910-004-0016-6.
Striking improvement of muscle strength under creatine therapy in a patient with long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency.
Korenke G, Wanders R, Hanefeld F
J Inherit Metab Dis. 2003; 26(1):67-8.
PMID: 12872842
DOI: 10.1023/a:1024031714659.
Pharmacokinetics of the dietary supplement creatine.
Persky A, Brazeau G, Hochhaus G
Clin Pharmacokinet. 2003; 42(6):557-74.
PMID: 12793840
DOI: 10.2165/00003088-200342060-00005.
Acute and moderate-term creatine monohydrate supplementation does not affect creatine transporter mRNA or protein content in either young or elderly humans.
Tarnopolsky M, Parise G, Fu M, Brose A, Parshad A, Speer O
Mol Cell Biochem. 2003; 244(1-2):159-66.
PMID: 12701826
Creatine supplementation in health and disease: what is the evidence for long-term efficacy?.
Derave W, Eijnde B, Hespel P
Mol Cell Biochem. 2003; 244(1-2):49-55.
PMID: 12701809